Research Topics
| M YchouSummaryAffiliation: Institut Paoli-Calmettes Country: France Publications
| Collaborators
|
Detail Information
Publications
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective studyAstrid Lievre
Gastroenterology and Digestive Oncology Unit, Assistance Publique Hopitaux de Paris, Hopital Ambroise Pare, Boulogne Billancourt, France
BMC Cancer 9:347. 2009..The aim of this study was to evaluate the activity of bevacizumab combined with FOLFIRI or FOLFOX in mCRC who have failed prior chemotherapy with fluoropyrimidine plus irinotecan and/or oxaliplatin...- A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancerM Ychou
CRLC Val d Aurelle, Montpellier, France
Ann Oncol 20:1964-70. 2009..This phase III trial compared FOLFIRI with simplified 5-FU/FA in this setting... - A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)M Ychou
Centre de Recherche et de Lutte contre le Cancer Val d Aurelle, Montpellier, France
Ann Oncol 20:674-80. 2009..This multicenter adjuvant phase III trial evaluated the addition of irinotecan to LV5FU2 in colon cancer patients at high risk of relapse... - Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastasesM Ychou
Centre Regional de Lutte contre le Cancer Val d Aurelle, 208 Rue des Apothicaires, 34298, Montpellier Cedex 05, France
Cancer Chemother Pharmacol 62:195-201. 2008..To assess the rate of R(0) resection of liver metastases achieved after chemotherapy with FOLFIRINOX... - Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOXT Mazard
Departement d Oncologie Medicale, CHU Saint Eloi, Montpellier, France
Cancer Chemother Pharmacol 69:807-14. 2012..Biweekly schedule of capecitabine combined with irinotecan (XELIRI), consecutively with irinotecan and oxaliplatin (XELIRINOX), was evaluated in patients with metastatic cancer from any solid tumors... - Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatmentE Samalin
CRLC Val d Aurelle, 208, rue des Apothicaires, 34298 Montpellier Cedex 5, France
Clin Res Hepatol Gastroenterol 35:48-54. 2011..We evaluated the efficacy of FOLFIRI regimen in a large retrospective series of MGA pts... - An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumorsM Ychou
Centre Val d Aurelle, Montpellier, France
Ann Oncol 14:481-9. 2003..The aim of this study was to determine the maximum-tolerated dose (MTD) and the recommended dose of irinotecan and oxaliplatin with a fixed 5-fluorouracil (5-FU)/leucovorin (LV) regimen in patients with metastatic solid tumors... - Phase-I/II radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable liver metastases from colorectal cancerM Ychou
Val d Aurelle Paul Lamarque Cancer Center, Montpellier, France
Int J Cancer 75:615-9. 1998..This phase-I/II study demonstrated that a dose of 300 mCi of 131I-F(ab')2 from the anti-CEA Mab F6 is well tolerated with bone-marrow rescue, whereas a dose of 200 mCi can be infused without severe bone-marrow toxicity... - Chemotherapy in carcinomas of unknown primary site: a high-dose intensity policyS Culine
Centre Regional de Lutte contre le Cancer Val d Aurelle, Montpellier, France
Ann Oncol 10:569-75. 1999..Unknown primary tumors are highly malignant diseases which portend a dire prognosis. We designed a prospective high dose-intensity policy with the aim of improving the results obtained with conventional chemotherapy... - A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancerA Ho-Pun-Cheung
Department of Biology, Val d Aurelle Cancer Institute, Montpellier, France
Pharmacogenomics J 11:437-43. 2011..005) and interleukin-13 (IL13) rs1800925 (P=0.0008) were significantly associated with tumor response to chemoradiation. These results reinforce the idea of using germline polymorphisms for personalized treatment... - 5-fluorouracil and leucovorin as second-line chemotherapy in carcinomas of unknown primary siteS Culine
Centre Regional de Lutte Contre le Cancer, Val d Aurelle, Montpellier, France
Anticancer Res 21:1455-7. 2001..From the start of second-line chemotherapy, the median overall survival was 3 months. The median overall survival from diagnosis was 9 months. Second-line chemotherapy with 5-FU/LV has no impact on survival in patients with CUP... - High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancerM Ychou
CRLC Val d Aurelle, 31 Rue de la croix verte, 34298 Montpellier Cedex 05, France
Cancer Chemother Pharmacol 50:383-91. 2002..The efficacy and safety of single-agent, high-dose irinotecan (CPT-11, Campto) 500 mg/m(2) every 3 weeks were investigated as first-line treatment for advanced colorectal cancer (CRC)... - [Contribution of endorectal ultrasonography in preoperative evaluation for very low rectal cancer]P Senesse
CRLC Val d Aurelle, Montpellier
Gastroenterol Clin Biol 25:24-8. 2001..Pretherapeutic evaluation of locoregional extension relies mainly on digital rectal examination. The interest of endorectal ultrasonography to assess lateral and inferior margins is still to be determined... - [Impact of mutational status of KRAS in the care of patients with colorectal cancer metastasis]E Assenat
CHU de Montpellier, CRLC Val d Aurelle, Service d Oncologie Digestive, 525, Rue de la Croix Verte, 34094 Montpellier, France
Bull Cancer 96:S41-6. 2009..In this article, we review the role and impact of mutational status of KRAS in the care of patients with colorectal cancer metastasis... - [Concomitant use of radiotherapy and gemcitabine: preclinical findings and clinical practice]D Azria
Département d Oncologie Radiothérapie, CRLC Val d Aurelle, 34298 Montpellier, France
Cancer Radiother 8:S106-13. 2004..This review summarizes the mechanisms of interaction between radiotherapy and gemcitabine and presents several therapeutic schemes for each tumor location... - Involvement of circulating CEA in liver metastases from colorectal cancers re-examined in a new experimental modelA Leconte
, CRLC Val d Aurelle Paul Lamarque Cancer Centre, , Montpellier, France
Br J Cancer 80:1373-9. 1999.... - Cost consequences of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French settingJ Y Douillard
Centre Rene Gauducheau, Nantes, France
Oncology 72:248-54. 2007..To compare the cost consequences of oral capecitabine and two different intravenous regimens of 5-fluorouracil/folinic acid (de Gramont and Mayo Clinic regimens) as adjuvant therapy in stage III colon cancer in France... - [A comparison of serum Cyfra 21-1 and SCC AG in the diagnosis of squamous cell esophageal carcinoma]M Ychou
CRLC Val-d'Aurelle-Paul-Lamarque, 34298 Montpellier
Bull Cancer 88:1023-7. 2001..This study confirms the value of Cyfra 21-1 in OSCC at the normal level of 1.5 ng/ml. The combination with SC improves the results. We now need to evaluate the role of these two markers in the follow up of oesophageal carcinoma... - A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a studyY Becouarn
Department of Digestive Oncology, Institut Bergonie, Regional Cancer Center, Bordeaux, France
Ann Oncol 18:2000-5. 2007..To assess activity and safety of an experimental combination of irinotecan and oxaliplatin (IRINOX) as first-line treatment in advanced colorectal cancer... - Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative StudyB Iacopetta
Universita di Palermo, Department of Oncology, Palermo, Italy
Ann Oncol 17:842-7. 2006.... - p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysisE Lopez-Crapez
Cancer Research Center, Val d Aurelle Cancer Institute, Montpellier 34298, France
Br J Cancer 92:2114-21. 2005..Our results do not support the use of p53 alterations alone as a predictive marker for response to radiotherapy in rectal carcinoma... - Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factorsS Cascinu
Azienda Ospedaliera di Parma, Parma, Italy
Ann Oncol 14:ii25-9. 2003.... - [Therapeutic management of hepatic metastases from colorectal cancers]F Lazorthes
Gastroenterol Clin Biol 27:B7. 2003 - Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancerD Fallik
Institut Gustave Roussy, Villejuif, France
Ann Oncol 14:856-63. 2003..This treatment seems to prevent extra-hepatic spread and prolong survival time. The results of this study have to be confirmed by new trials using more active systemic chemotherapy... - [Chemoradiotherapy in the adjuvant treatment of gastric adenocarcinomas: real progress?]L Mineur
Institut Sainte Catherine, Chemin du Lavarin, 84082 Avignon, France
Cancer Radiother 6:13s-23s. 2002..Of the 281 patients, 17% stopped treatment because toxic effects. Technical modalities of radiotherapy and post-operative nutrition support, which are critical points of interest for this treatment, are also discussed... - Docetaxel and radiotherapy and pancreatic cancerF Viret
Department of Medicine, Institut Paoli Calmettes, Marseille, France
Pancreas 27:214-9. 2003..We conducted a phase 1 trial to determine the maximum tolerated dose (MTD) of weekly docetaxel delivered concurrently with radiation therapy for the treatment of locally advanced adenocarcinoma of the pancreas... - Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancerD Azria
Tumour Immunotargeting and Antibody Engineering, INSERM, EMI 0227, 34298 Montpellier, France
Br J Cancer 89:1987-94. 2003..These results suggest that TNFalpha in combination with BAb and RT may be beneficial for the treatment of pancreatic cancer in locally advanced or adjuvant settings... - Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patientsJ F Seitz
Institut Paoli Calmettes, University of the Mediterranean, Marseille, France
Ann Oncol 13:1072-9. 2002..This multicenter, phase II, open-label study evaluated the antitumor efficacy and safety of oxaliplatin and raltitrexed (Tomudex) in non-pretreated advanced colorectal cancer patients... - [Clinical practice guidelines: 2004 Standards, Options and Recommendations for the management of patient with adenocarcinoma of the stomach--radiotherapy.]M Ychou
Cancer Radiother 8:322-35. 2004..Adjuvant concomitant chemoradiotherapy can be administered to patients without denutrition with DI or D2 lymphadenectomy and with involvement of regional lymph nodes (N2 or N3)... - Efficacy of prophylactic anti-diarrhoeal treatment in patients receiving Campto for advanced colorectal cancerJ Duffour
Hopital La Timone, 264 rue St-Pierre, Marseille, France
Anticancer Res 22:3727-31. 2002..Preventive combined treatment is effective in reducing the incidence of severe delayed diarrhoea, and it should be proposed to patients treated with mono-therapy Campto(r) and evaluated in poly-chemotherapy protocols... - A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinomaM Ducreux
Institut Gustave Roussy, Service d Oncologie Digestive, Villejuif, France
Ann Oncol 13:1185-91. 2002..5% response rate and a 29% survival rate at 1 year. The present study aimed to compare FUP with 5-FU alone, which was the control arm in former Mayo Clinic trials... - Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801)O Bouche
University Hospital, Reims, France
Ann Oncol 16:1488-97. 2005..The aim of this study was to evaluate the efficacy of adjuvant chemotherapy after resection for gastric cancer in a randomized controlled trial... - [Recommendations for clinical practice: management of stomach adenocarcinoma]M Ychou
Centre Val d'Aurelle, Montpellier
Bull Cancer 93:192-6. 2006 - Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumoursW Jacot
Br J Dermatol 151:238-41. 2004